Company intelligence / Profile preview
NanOlogy
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
Overview
NanOlogy has developed a proprietary supercritical precipitation technology to create large surface area microparticles of chemotherapeutic agents for intratumoral delivery. Over 170 patients have been treated in clinical trials across multiple solid tumor types. Results show promising tumor response and immunomodulation with minimal systemic toxicity and no confirmed drug-related serious adverse events.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeNanoparticle (specifically, large surface area microparticles/LSAMs)Polymer-drug conjugate therapy (via Purcision platform)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on NanOlogy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanOlogy.